Cited by 2,050HIV Research and TreatmentHIV/AIDS drug development and treatmentInfectious Diseases and Tuberculosis

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection

Chun, Tae-Wook, Carruth, Lucy, Finzi, Diana, Shen, Xuefei, DiGiuseppe, Joseph A., Taylor, Harry, Hermankova, Monika, Chadwick, Karen, Margolick, Joseph, Quinn, Thomas C., Kuo, Yen-Hong, Brookmeyer, Ronald, Zeiger, Martha A., Barditch-Crovo, Patricia, Siliciano, Robert F.·1997·Nature

DOI 10.1038/387183a0

Open this paper in CoChat — free account

Abstract

The capacity of HIV-1 to establish latent infection of CD4+ T cells may allow viral persistence despite immune responses and antiretroviral therapy. Measurements of infectious virus and viral RNA in plasma and of infectious virus, viral DNA and viral messenger RNA species in infected cells all suggest that HIV-1 replication continues throughout the course of infection. Uncertainty remains over what fraction of CD4+ T cells are infected and whether there are latent reservoirs for the virus. We show here that during the asymptomatic phase of infection there is an extremely low total body load of latently infected resting CD4+ T cells with replication-competent integrated provirus (<10(7) cells). The most prevalent form of HIV-1 DNA in resting and activated CD4+ T cells is a full-length, linear, unintegrated form that is not replication competent. The infection progresses even though at any given time in the lymphoid tissues integrated HIV-1 DNA is present in only a minute fraction of the susceptible populations, including resting and activated CD4+ T cells and macrophages.

Integrity signals

Registry

Crossref · 10.1038/387183a0

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M., & Markowitz, M. H. (1995) · Nature · doi:10.1038/373123a0 · Cited by 4,261
HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time
Perelson, A. S., Neumann, A. U., Markowitz, M. H., Leonard, J. M., & Ho, D. D. (1996) · Science · doi:10.1126/science.271.5255.1582 · Cited by 3,533
Viral dynamics in human immunodeficiency virus type 1 infection
Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deutsch, P., Lifson, J. D., Bonhoeffer, S., Nowak, M. A., Hahn, B. H., et al. (1995) · Nature · doi:10.1038/373117a0 · Cited by 3,259
Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma
Mellors, J. W., Rinaldo, C. R., Gupta, P., White, R. M., Todd, J. A., & Kingsley, L. (1996) · Science · doi:10.1126/science.272.5265.1167 · Cited by 2,658
HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy
Coffin, J. M. (1995) · Science · doi:10.1126/science.7824947 · Cited by 1,963
Decay characteristics of HIV-1-infected compartments during combination therapy
Perelson, A. S., Essunger, P., Cao, Y., Vesanen, M., Hurley, A., Saksela, K., Markowitz, M. H., & Ho, D. D. (1997) · Nature · doi:10.1038/387188a0 · Cited by 1,861
The Role of Mononuclear Phagocytes in HTLV-III/LAV Infection
Gartner, S., Markovits, P., Markovitz, D. M., Kaplan, M. H., Gallo, R. C., & Popovič, M. (1986) · Science · doi:10.1126/science.3014648 · Cited by 1,808
HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease
Pantaleo, G., Graziosi, C., Demarest, J. F., Butini, L., Montroni, M., Fox, C. H., Orenstein, J. M., Kotler, D. P., & Fauci, A. S. (1993) · Nature · doi:10.1038/362355a0 · Cited by 1,808
HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure
Zack, J. A., Arrigo, S. J., Weitsman, S. R., Go, A. S., Haislip, A., & Chen, I. S. Y. (1990) · Cell · doi:10.1016/0092-8674(90)90802-l · Cited by 1,517
Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS
Embretson, J. E., Zupancic, M., Ribas, J. L., Burke, A., Rácz, P., Tenner‐Racz, K., & Haase, A. T. (1993) · Nature · doi:10.1038/362359a0 · Cited by 1,419

Flagged first, then by citations

Show all 29 references

Sorted by citations

Items 901–1,000 of 1,000

Expression of the c-myc Proto-oncogene Is Essential for HIV-1 Infection in Activated T Cells
Sun, Y., & Clark, E. A. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1391 · Cited by 31
CD80 and CD86 costimulatory molecules on circulating T cells of HIV infected individuals
Köchli, C., Wendland, T., Frutig, K., Grunow, R., Merlin, S., & Pichler, W. J. (1999) · Immunology Letters · doi:10.1016/s0165-2478(98)00107-2 · Cited by 31
Novel histone deacetylase inhibitor NCH-51 activates latent HIV-1 gene expression
Victoriano, A. F. B., Imai, K., Togami, H., Ueno, T., Asamitsu, K., Suzuki, T., Miyata, N., Ochiai, K., & Okamoto, T. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.03.017 · Cited by 30
Reduced Frequency of Cells Latently Infected With Replication-Competent Human Immunodeficiency Virus-1 in Virally Suppressed Individuals Living in Rakai, Uganda
Prodger, J. L., Lai, J., Reynolds, S. J., Keruly, J. C., Moore, R. D., Kasule, J., Kityamuweesi, T., Buule, P., Serwadda, D., Nason, M., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix478 · Cited by 30
Self-citation
The Female Genital Tract Microbiome Is Associated With Vaginal Antiretroviral Drug Concentrations in Human Immunodeficiency Virus–Infected Women on Antiretroviral Therapy
Carlson, R. D., Sheth, A. N., Read, T. D., Frisch, M. B., Mehta, C. C., Martin, A. M., Haaland, R. E., Patel, A. S., Pau, C., Kraft, C. S., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix420 · Cited by 30
Colon dysregulation in methamphetamine self-administering HIV-1 transgenic rats
Persons, A. L., Bradaric, B. D., Dodiya, H. B., Ohene‐Nyako, M., Forsyth, C. B., Keshavarzian, A., Shaikh, M. W., & Napier, T. C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190078 · Cited by 30
A novel function for spumaretrovirus integrase: an early requirement for integrase-mediated cleavage of 2 LTR circles
Delelis, O., Petit, C., Leh, H., Mbemba, G., Mouscadet, J. F., & Sonigo, P. (2005) · Retrovirology · doi:10.1186/1742-4690-2-31 · Cited by 30
Targeting IκB Proteins for HIV Latency Activation: the Role of Individual IκB and NF-κB Proteins
Fernández, G., Zaikos, T. D., Khan, S. Z., Jacobi, A. M., Behlke, M. A., & Zeichner, S. L. (2013) · Journal of Virology · doi:10.1128/jvi.03251-12 · Cited by 30
Early Combination Antiretroviral Therapy Limits HIV-1 Persistence in Children
Luzuriaga, K. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-091114-111159 · Cited by 30
The Alphabet Soup of HIV Reservoir Markers
Sharaf, R., & Li, J. Z. (2017) · Current HIV/AIDS Reports · doi:10.1007/s11904-017-0355-y · Cited by 30
Integration of HIV-1 DNA Is Regulated by Interplay between Viral Rev and Cellular LEDGF/p75 Proteins
Levin, A., Rosenbluh, J., Hayouka, Z., Friedler, A., & Loyter, A. (2009) · Molecular Medicine · doi:10.2119/molmed.2009.00133 · Cited by 30
Rapid Expression of Human Immunodeficiency Virus following Activation of Latently Infected Cells
Arlen, P. A., Brooks, D. G., Gao, L. Y., Vatakis, D. N., Brown, H. J., & Zack, J. A. (2006) · Journal of Virology · doi:10.1128/jvi.80.3.1599-1603.2006 · Cited by 30
The effects of an HIV‐1 immunogen (Remune) on viral load, CD4 cell counts and HIV‐specific immunity in a double‐blind, randomized, adjuvant‐controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs
Turner, J. R., Kostman, J., Aquino, A., Wright, D., Szabo, S. M., Bidwell, R., Goodgame, J., Daigle, A. E., Kelley, E., Jensen, F., et al. (2001) · HIV Medicine · doi:10.1046/j.1468-1293.2001.00051.x · Cited by 30
Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy
Pomerantz, R. J. (2001) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(00)00016-0 · Cited by 30
Transcriptional activation of HIV byMycobacterium tuberculosisin human monocytes
Toossi, Z., Xia, L., Wu, M., & Salvekar, A. (1999) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1999.00952.x · Cited by 30
Quantitative DNA proviral detection in HIV-1 patients treated with antiretroviral therapy
Vitone, F., Gibellini, D., Schiavone, P., & Re, M. C. (2004) · Journal of Clinical Virology · doi:10.1016/j.jcv.2004.11.003 · Cited by 30
Current strategies in the treatment of HIV infection
Cohen, O. J., & Fauci, A. S. (2002) · Disease-a-Month · doi:10.1067/mda.2002.124659 · Cited by 30
Considerations in the development of nonhuman primate models of combination antiretroviral therapy for studies of aids virus suppression, residual virus, and curative strategies
Prete, G. Q. D., & Lifson, J. D. (2013) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e328361cf40 · Cited by 30
Dynamics of the HIV infection under antiretroviral therapy: A cellular automata approach
González, R. E. R., Coutinho, S., dos Santos, R. M. Z., & de Figueirêdo, P. H. (2013) · Physica A Statistical Mechanics and its Applications · doi:10.1016/j.physa.2013.05.056 · Cited by 29
Development of co-selected single nucleotide polymorphisms in the viral promoter precedes the onset of human immunodeficiency virus type 1-associated neurocognitive impairment
Li, L., Aiamkitsumrit, B., Pirrone, V., Nonnemacher, M. R., Wojno, A. P., Passic, S. R., Flaig, K. E., Kilareski, E. M., Blakey, B., Ku, J., et al. (2011) · Journal of NeuroVirology · doi:10.1007/s13365-010-0014-1 · Cited by 29
Intensifying Antiretroviral Therapy With Raltegravir and Maraviroc During Early Human Immunodeficiency Virus (HIV) Infection Does Not Accelerate HIV Reservoir Reduction
Ostrowski, M., Benko, E., Yue, F. Y., Kim, C. J., Huibner, S., Lee, T., Singer, J., Pankovich, J., Laeyendecker, O. B., Kaul, R., et al. (2015) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofv138 · Cited by 29
HIV reservoirs: the new frontier.
Iglesias-Ussel, M. D., & Romerio, F. (2011) · PubMed · Cited by 29
Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV
Rochat, M.-A., Schlaepfer, E., & Speck, R. F. (2016) · Journal of Virology · doi:10.1128/jvi.02084-16 · Cited by 29
Clonal Expansion of Human Immunodeficiency Virus–Infected Cells and Human Immunodeficiency Virus Persistence During Antiretroviral Therapy
Mullins, J. I., & Frenkel, L. M. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw636 · Cited by 29
Peering into the HIV reservoir
García, M., Buzón, M. J., Benito, J. M., & Rallón, N. I. (2018) · Reviews in Medical Virology · doi:10.1002/rmv.1981 · Cited by 32
Novel gRNA design pipeline to develop broad-spectrum CRISPR/Cas9 gRNAs for safe targeting of the HIV-1 quasispecies in patients
Sullivan, N. T., Dampier, W., Chung, C.-H., Allen, A. G., Atkins, A., Pirrone, V., Homan, G., Passic, S. R., Williams, J. W., Zhong, W., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-52353-9 · Cited by 32
Chromatin maturation of the HIV-1 provirus in primary resting CD4+ T cells
Lindqvist, B., Akusjärvi, S. S., Sönnerborg, A. B., Dimitriou, M., & Svensson, J. P. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008264 · Cited by 30
Targeted Chromatinization and Repression of HIV-1 Provirus Transcription with Repurposed CRISPR/Cas9
Olson, A., Basukala, B., Lee, S., Gagné, M., Wong, W. W., & Henderson, A. J. (2020) · Viruses · doi:10.3390/v12101154 · Cited by 29
Tissue‐specific differences in HIV DNA levels and mechanisms that govern HIV transcription in blood, gut, genital tract and liver in ART‐treated women
Morón‐López, S., Xie, G., Kim, P., Siegel, D. A., Lee, S. A., Wong, J. K., Price, J. C., El‐Nachef, N., Greenblatt, R. M., Tien, P. C., et al. (2021) · Journal of the International AIDS Society · doi:10.1002/jia2.25738 · Cited by 29
HIV-1-infected CD8+CD4+ T cells decay in vivo at a similar rate to infected CD4 T cells during HAART
Hughes, G. J., Cochrane, A., Leen, C. L. S., Morris, S., Bell, J. E., & Peter Simmonds, K. (2008) · AIDS · doi:10.1097/qad.0b013e3282f151b9 · Cited by 30
Establishment and Maintenance of HIV Latency: Model Systems and Opportunities for Intervention
Marsden, M. D., & Zack, J. A. (2009) · Future Virology · doi:10.2217/fvl.09.70 · Cited by 30
Histone Deacetylase Inhibitor Romidepsin InhibitsDe NovoHIV-1 Infections
Jønsson, K. L., Tolstrup, M., Vad‐Nielsen, J., Kjær, K., Laustsen, A., Andersen, M. N., Rasmussen, T. A., Søgaard, O. S., Østergaard, L. J., Denton, P. W., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00574-15 · Cited by 29
Application and Impact of Population Pharmacokinetics in the Assessment of Antiretroviral Pharmacotherapy
Barrett, J. S., Labb, L., & Pfister, M. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544060-00003 · Cited by 29
Impact of Chemotherapy for HIV-1 Related Lymphoma on Residual Viremia and Cellular HIV-1 DNA in Patients on Suppressive Antiretroviral Therapy
Cillo, A. R., Krishnan, S., McMahon, D. K., Mitsuyasu, R. T., Para, M. F., & Mellors, J. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092118 · Cited by 29
A CRISPR/Cas9 guidance RNA screen platform for HIV provirus disruption and HIV/AIDS gene therapy in astrocytes
Huang, Z., & Nair, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-06269-x · Cited by 29
Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors
Jean, M. J., Fiches, G. N., Hayashi, T., & Zhu, J. K. (2018) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2018.0153 · Cited by 31
Modeling the immune response to HIV infection
Conway, J. M., & Ribeiro, R. M. (2018) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2018.10.006 · Cited by 29
Persistent Viral Reservoirs in Lymphoid Tissues in SIV-Infected Rhesus Macaques of Chinese-Origin on Suppressive Antiretroviral Therapy
Siddiqui, S., Perez, S., Gao, Y., Doyle‐Meyers, L. A., Foley, B. T., Li, Q., & Ling, B. (2019) · Viruses · doi:10.3390/v11020105 · Cited by 32
Hydroxyurea and Interleukin-6 Synergistically Reactivate HIV-1 Replication in a Latently Infected Promonocytic Cell Line via SP1/SP3 Transcription Factors
Oguariri, R. M., Brann, T. W., & Imamichi, T. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m608150200 · Cited by 29
The Role of Hydroxyurea in Enhancing the Virologic Control Achieved Through Structured Treatment Interruption in Primary HIV Infection
Bloch, M. T., Smith, D. E., Quan, D., Kaldor, J. M., Zaunders, J., Petoumenos, K., Irvine, K., Law, M. G., Grey, P., Finlayson, R. J., et al. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000219779.50668.e6 · Cited by 29
Fusion-Induced Apoptosis Contributes to Thymocyte Depletion by a Pathogenic Human Immunodeficiency Virus Type 1 Envelope in the Human Thymus
Meissner, E. G., Zhang, L., Jiang, S., & Su, L. (2006) · Journal of Virology · doi:10.1128/jvi.01382-06 · Cited by 29
Ribozymes in gene therapy of HIV-1
Macpherson, J. L. (1999) · Frontiers in bioscience · doi:10.2741/macpherson · Cited by 29
Mutation Takes No Vacation: Can Structured Treatment Interruptions Increase the Risk of Drug-Resistant HIV-1?
Dorman, K. S., Kaplan, A. H., Lange, K. L., & Sinsheimer, J. S. (2000) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200012150-00003 · Cited by 29
Infection of HIV-1 Transgenic Mice with Mycobacterium avium Induces the Expression of Infectious Virus Selectively from a Mac-1-Positive Host Cell Population
Doherty, T. M., Chougnet, C. A., Schito, M. L., Patterson, B. K., Fox, C. H., Shearer, G. M., Englund, G., & Sher, A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1506 · Cited by 29
mRNA-based HIV-1 vaccines
Ahmed, S., & Herschhorn, A. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00041-24 · Cited by 29
DNA cleavage enzymes for treatment of persistent viral infections: Recent advances and the pathway forward
Weber, N. D., Aubert, M., Dang, C. H., Stone, D., & Jerome, K. R. (2014) · Virology · doi:10.1016/j.virol.2013.12.037 · Cited by 28
In vivo platforms for analysis of HIV persistence and eradication
García, J. V. (2016) · Journal of Clinical Investigation · doi:10.1172/jci80562 · Cited by 28
Notwithstanding Circumstantial Alibis, Cytotoxic T Cells Can Be Major Killers of HIV-1-Infected Cells
Gadhamsetty, S., Coorens, T. H. H., & de Boer, R. J. (2016) · Journal of Virology · doi:10.1128/jvi.00306-16 · Cited by 28
Long non-coding RNAs and latent HIV – A search for novel targets for latency reversal
Trypsteen, W., White, C., Mukim, A., Spina, C. A., Spiegelaere, W. D., Lefever, S., Planelles, V., Bosque, A., Woelk, C. H., Vandekerckhove, L., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224879 · Cited by 30
Antibody Conjugates for Targeted Therapy Against HIV-1 as an Emerging Tool for HIV-1 Cure
Umotoy, J. C., & de Taeye, S. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.708806 · Cited by 29
HIV-1 fitness and macrophages
Goodenow, M. M., Rose, S. L., Tuttle, D. L., & Sleasman, J. W. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0403186 · Cited by 28
Transcriptional Control of HIV Replication by Multiple Modulators and Their Implication for a Novel Antiviral Therapy
Victoriano, A. F. B., & Okamoto, T. (2011) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2011.0263 · Cited by 28
Quantification of viral DNA during HIV-1 infection: A review of relevant clinical uses and laboratory methods
Alidjinou, E. K., Bocket, L., & Hober, D. (2014) · Pathologie Biologie · doi:10.1016/j.patbio.2014.07.007 · Cited by 32
Latency profiles of full length HIV-1 molecular clone variants with a subtype specific promoter
van der Sluis, R. M., Pollakis, G., van Gerven, M. L., Berkhout, B., & Jeeninga, R. E. (2011) · Retrovirology · doi:10.1186/1742-4690-8-73 · Cited by 29
Potential Implication of Residual Viremia in Patients on Effective Antiretroviral Therapy
Sahu, G. K. (2014) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2014.0194 · Cited by 28
Quantitation of integrated proviral DNA in viral reservoirs
Graf, E. H., & O’Doherty, U. (2013) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32835d8132 · Cited by 28
Loss of immune homeostasis dictates SHIV rebound after stem-cell transplantation
Peterson, C. W., Benne, C., Polacino, P. S., Kaur, J., McAllister, C. E., Filali-Mouhim, A., Obenza, W., Pecor, T., Huang, M.-L. W., Baldessari, A. E., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.91230 · Cited by 28
SUN2 Modulates HIV-1 Infection and Latency through Association with Lamin A/C To Maintain the Repressive Chromatin
Sun, W., Jiao, S., Sun, L. X., Zhou, Z., Jin, X., & Wang, J. (2018) · mBio · doi:10.1128/mbio.02408-17 · Cited by 28
An anti-CD45RO immunotoxin eliminates T cells latently infected with HIV-1 in vitro
McCoig, C. C., Dyke, G. V., Chou, C.-S., Picker, L. J., Ramilo, O., & Vitetta, E. S. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11482 · Cited by 28
Evolution of R5 and X4 human immunodeficiency virus type 1 gag sequences in vivo: evidence for recombination
van Rij, R. P., Worobey, M., Visser, J. A., & Schuitemaker, H. (2003) · Virology · doi:10.1016/s0042-6822(03)00454-9 · Cited by 28
The Duration of Exposure to HIV Modulates the Breadth and the Magnitude of HIV-Specific Memory CD4+ T Cells
Younes, S., Trautmann, L., Yassine‐Diab, B., Kalfayan, L. H., Kernaleguen, A., Cameron, T. O., Boulassel, R., Stern, L. J., Routy, J., Grossman, Z., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.2.788 · Cited by 28
Quantification of intrinsic residual viral replication in treated HIV-infected patients
Fraser, C., Ferguson, N. M., & Anderson, R. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261283598 · Cited by 28
Evolution of Total and Integrated HIV-1 DNA and Change in DNA Sequences in Patients with Sustained Plasma Virus Suppression
Izopet, J., Cazabat, M., Pasquier, C., Sauné, K., Bonnet, É., Marchou, B., Massip, P., & Puel, J. (2002) · Virology · doi:10.1006/viro.2002.1621 · Cited by 28
Deep mutational scanning reveals functional constraints and antibody-escape potential of Lassa virus glycoprotein complex
Carr, C. R., Crawford, K. H. D., Murphy, M., Galloway, J., Haddox, H. K., Matsen, F. A., IV, Andersen, K. G., King, N. P., & Bloom, J. D. (2024) · Immunity · doi:10.1016/j.immuni.2024.06.013 · Cited by 29
An “Escape Clock” for Estimating the Turnover of SIV DNA in Resting CD4+ T Cells
Reece, J. C., Petravic, J., Balamurali, M., Loh, L., Gooneratne, S. L., Rose, R. D., Kent, S. J., & Davenport, M. P. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002615 · Cited by 27
Fingolimod retains cytolytic T cells and limits T follicular helper cell infection in lymphoid sites of SIV persistence
Pino, M., Paganini, S., Deléage, C., Padhan, K., Harper, J. L., King, C. T., Micci, L., Cervasi, B., Mudd, J. C., Gill, K., et al. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1008081 · Cited by 27
Diversity of small molecule HIV‐1 latency reversing agents identified in low‐ and high‐throughput small molecule screens
Hashemi, P., & Sadowski, I. (2019) · Medicinal Research Reviews · doi:10.1002/med.21638 · Cited by 30
Regulatory T cells: the ultimate HIV reservoir?
Rocco, J. M., Mellors, J. W., & Macatangay, B. J. C. (2018) · Journal of Virus Eradication · doi:10.1016/s2055-6640(20)30305-8 · Cited by 27
Thiostrepton Reactivates Latent HIV-1 through the p-TEFb and NF-κB Pathways Mediated by Heat Shock Response
Peng, W., Hong, Z., Chen, X., Gao, H., Dai, Z., Zhao, J., Liu, W., Li, D., & Deng, K. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02328-19 · Cited by 27
HIV persistence in lymph nodes
Banga, R., Muñoz, O., & Perreau, M. (2021) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000686 · Cited by 28
Allogeneic immunity clears latent virus following allogeneic stem cell transplantation in SIV-infected ART-suppressed macaques
Wu, H. L., Busman‐Sahay, K., Weber, W. C., Waytashek, C. M., Boyle, C. D., Bateman, K. B., Reed, J. S., Hwang, J. M., Shriver-Munsch, C. M., Swanson, T., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.04.019 · Cited by 27
Self-citation
Humanized Mice for Studies of HIV-1 Persistence and Elimination
Zhang, C., Zaman, L. A., Poluektova, L. Y., Gorantla, S., Gendelman, H. E., & Dash, P. K. (2023) · Pathogens · doi:10.3390/pathogens12070879 · Cited by 29
The Complex Dysregulations of CD4 T Cell Subtypes in HIV Infection
Tolomeo, M., & Cascio, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147512 · Cited by 28
Mucosal and Peripheral Lin − HLA-DR + CD11c/123 − CD13 + CD14 − Mononuclear Cells Are Preferentially Infected during Acute Simian Immunodeficiency Virus Infection
Moore, A. C., Bixler, S. L., Lewis, M. G., Verthelyi, D. I., & Mattapallil, J. J. (2011) · Journal of Virology · doi:10.1128/jvi.06372-11 · Cited by 27
Valproic acid: a potential role in treating latent HIV infection
Routy, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67074-2 · Cited by 27
Paucity of Intact Non-Induced Provirus with Early, Long-Term Antiretroviral Therapy of Perinatal HIV Infection
Rainwater‐Lovett, K., Ziemniak, C., Watson, D. C., Luzuriaga, K., Siberry, G. K., Petru, A. M., Chen, Y., Uprety, P., McManus, M. M., Ho, Y., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170548 · Cited by 29
Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents
Petravic, J., Rasmussen, T. A., Lewin, S. R., Kent, S. J., & Davenport, M. P. (2017) · Journal of Virology · doi:10.1128/jvi.02092-16 · Cited by 27
Persistence of replication-competent HIV in both memory and naive CD4 T cell subsets in patients on prolonged and effective HAART
Lambotte, O., Demoustier, A., de Herve, M.-G. D. G., Wallon, C., Gasnault, J., Goujard, C., Delfraissy, J. F., & Taoufik, Y. (2002) · AIDS · doi:10.1097/00002030-200211080-00007 · Cited by 27
Ethanol enhances TNF-α–inducible NFκB activation and HIV-1-LTR transcription in CD4+ Jurkat T lymphocytes
Dong, Q. D., Kelkar, S., Xiao, Y., Joshi‐Barve, S., McClain, C. J., & Barve, S. S. (2000) · Journal of Laboratory and Clinical Medicine · doi:10.1067/mlc.2000.110104 · Cited by 27
GB virus C (GBV-C) infection in patients with chronic hepatitis C. Influence on liver disease and on hepatitis virus behaviour: Effect of interferon alfa therapy
Pawlotsky, J., Roudot‐Thoraval, F., Muerhoff, A. S., Pellerin, M., Germanidis, G. S., Desai, S. M., Bastie, A., Darthuy, F., Rémiré, J., Zafrani, E., et al. (1998) · Journal of Medical Virology · doi:10.1002/(sici)1096-9071(199801)54:1 · Cited by 28
Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy
van Praag, R. M. E., Wit, F. W. N. M., Jurriaans, S., de Wolf, F., Prins, J. M., & Lange, J. M. A. (2002) · AIDS · doi:10.1097/00002030-200203290-00007 · Cited by 27
Summary of the international consensus symposium on management of HIV, CMV and hepatitis virus infections
de Jong, M. D., Boucher, C. A., Danner, S. A., Gazzard, B., Griffiths, P. D., Katlama, C., Lange, J. M. A., Richman, D. D., & Vella, S. (1998) · Antiviral Research · doi:10.1016/s0166-3542(97)00059-4 · Cited by 27
Therapeutic targeting of human immunodeficiency virus type-1 latency: current clinical realities and future scientific possibilities
Butera, S. T. (2000) · Antiviral Research · doi:10.1016/s0166-3542(00)00133-9 · Cited by 27
New Tools for Quantifying HIV-1 Reservoirs: Plasma RNA Single Copy Assays and Beyond
Hilldorfer, B. B., Cillo, A. R., Besson, G. J., Bedison, M. A., & Mellors, J. W. (2012) · Current HIV/AIDS Reports · doi:10.1007/s11904-011-0104-6 · Cited by 26
Simian immunodeficiency virus macaque models of HIV latency
Deere, J. D., Schinazi, R. F., & North, T. W. (2010) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32834086ce · Cited by 30
Increasing the Clinical Potential and Applications of Anti-HIV Antibodies
Hua, C. K., & Ackerman, M. E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01655 · Cited by 27
Isolation, Synthesis, and Structure–Activity Relationship Study on Daphnane and Tigliane Diterpenes as HIV Latency-Reversing Agents
El‐Desoky, A. H., Eguchi, K., Kishimoto, N., Asano, T., Kato, H., Hitora, Y., Kotani, S., Nakamura, T., Tsuchiya, S., Kawahara, T., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01973 · Cited by 26
Circulating Monocytes Are Not a Major Reservoir of HIV-1 in Elite Suppressors
Spivak, A. M., Salgado, M., Rabi, S. A., O’Connell, K. A., & Blankson, J. N. (2011) · Journal of Virology · doi:10.1128/jvi.05409-11 · Cited by 26
Endothelial Cell Stimulation Overcomes Restriction and Promotes Productive and Latent HIV-1 Infection of Resting CD4 + T Cells
Shen, A., Baker, J. J., Scott, G. L., Davis, Y. P., Ho, Y.-Y., & Siliciano, R. F. (2013) · Journal of Virology · doi:10.1128/jvi.01478-13 · Cited by 26
Self-citation
Discovery of a Small Molecule Agonist of Phosphatidylinositol 3-Kinase p110α That Reactivates Latent HIV-1
Doyon, G., Sobolewski, M. D., Huber, K. D., McMahon, D. K., Mellors, J. W., & Sluis‐Cremer, N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084964 · Cited by 26
New approaches for quantitating the inhibition of HIV-1 replication by antiviral drugs in vitro and in vivo
McMahon, M. A., Shen, L., & Siliciano, R. F. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328332c54d · Cited by 26
Self-citation
Promoter Targeting RNAs: Unexpected Contributors to the Control of HIV-1 Transcription
Suzuki, K., Ahlenstiel, C., Marks, K., & Kelleher, A. D. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.67 · Cited by 26
Short Communication: Seminal Reservoirs during an HIV Type 1 Eradication Trial
Nunnari, G., Leto, D., Sullivan, J., Xu, Y., Mehlman, K. E., Kulkosky, J., & Pomerantz, R. J. (2005) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2005.21.768 · Cited by 26
The Majority of CD4 + T-Cell Depletion during Acute Simian-Human Immunodeficiency Virus SHIV89.6P Infection Occurs in Uninfected Cells
Matrajt, L., Younan, P. M., Kiem, H., & Schiffer, J. T. (2014) · Journal of Virology · doi:10.1128/jvi.03428-13 · Cited by 26
A Real Time PCR Platform for the Simultaneous Quantification of Total and Extrachromosomal HIV DNA Forms in Blood of HIV-1 Infected Patients
Casabianca, A., Orlandi, C., Canovari, B., Scotti, M., Acetoso, M., Valentini, M., Petrelli, E., & Magnani, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111919 · Cited by 27
Harnessing the Prokaryotic Adaptive Immune System as a Eukaryotic Antiviral Defense
Price, A. A., Grakoui, A., & Weiss, D. S. (2016) · Trends in Microbiology · doi:10.1016/j.tim.2016.01.005 · Cited by 26
The Role of Caveolin 1 in HIV Infection and Pathogenesis
Mergia, A. (2017) · Viruses · doi:10.3390/v9060129 · Cited by 29
Nonhuman Primate Models for Studies of AIDS Virus Persistence During Suppressive Combination Antiretroviral Therapy
Prete, G. Q. D., & Lifson, J. D. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_73 · Cited by 26
Elimination of HIV-1 Latently Infected Cells by Gnidimacrin and a Selective HDAC Inhibitor
Huang, L., Lai, W.-H., Zhu, L., Li, W., Wei, L., Lee, K., Xie, L., & Chen, C. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00012 · Cited by 26
Untitled work
Wood (1999) · doi:10.1002/(sici)1096-9071(199906)58:2

Authors: Chun, T.-W., Carruth, L., Finzi, D., Shen, X., DiGiuseppe, J. A., Taylor, H., Hermankova, M., Chadwick, K., Margolick, J., Quinn, T. C., Kuo, Y.-H., Brookmeyer, R., Zeiger, M. A., Barditch-Crovo, P., & Siliciano, R. F.
Affiliations: Johns Hopkins University (US)
National Institutes of Health (US)
ORCID: Chun, Tae-Wook
DiGiuseppe, Joseph A.
Margolick, Joseph
Quinn, Thomas C.
Kuo, Yen-Hong
Zeiger, Martha A.
Siliciano, Robert F.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 1997-05
Volume: 387
Issue: 6629
Pages: 183-188
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/387183a0
OpenAlex: W2030844138
Cited by: 2,050
References: 29
Citations by year: 2026: 29 · 2025: 47 · 2024: 48 · 2023: 59 · 2022: 54 · 2021: 56 · 2020: 80 · 2019: 79 · 2018: 102 · 2017: 81 · 2016: 98 · 2015: 79 · 2014: 86 · 2013: 87 · 2012: 74
FWCI: 25.32
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Topics: Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
Keywords: HIV-1, latent viral reservoir, CD4+ T cells, integrated provirus, viral persistence, asymptomatic HIV infection, activated T cells, macrophages, viral DNA, viral RNA, antiretroviral therapy
MeSH terms: Cells, Cultured, DNA, Viral, Humans, Immunologic Memory, Lymph Nodes, Lymphocyte Activation, Macrophages, Proviruses, Virus Replication, CD4-Positive T-Lymphocytes, HIV-1, HIV Infections, Polymerase Chain Reaction, Virus Integration, Leukocyte Common Antigens, Virus Latency, Coculture Techniques, Anti-HIV Agents, Viral Load

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks